Manthan Meeting-Transforming the Treatment Paradigm for patients with R/R Adult

Speciality: All Speciality

Description:

A warm welcome to all the medical professionals in this interesting session on Manthan Meeting - Inotuzumab: Transforming the Treatment Paradigm for patients with R/R Adult B Cell ALL
The Manthan Meeting is a prominent conference that brings together leading hematologists, oncologists, and researchers to discuss transformative treatments for hematological malignancies. A key focus of the meeting is on the innovative use of Inotuzumab ozogamicin in the treatment of relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (ALL).
Inotuzumab ozogamicin is a groundbreaking antibody-drug conjugate that targets CD22, a surface antigen commonly expressed on B-cell ALL cells. By delivering a cytotoxic agent directly to the cancer cells, Inotuzumab offers a novel mechanism of action that has shown impressive efficacy in clinical trials, significantly improving remission rates for patients with R/R B-cell ALL.
Inotuzumab has changed this outlook by providing a potent, targeted therapy that offers new hope for achieving remission and extending survival in this challenging patient population.
Therefore, get an overall knowledge of update manthan meeting - inotuzumab: transforming the treatment paradigm for patients with R/R Adult B Cell ALL
 

See More Webinars @ Hidoc Webinars